JPMorgan upgraded IGM Biosciences (IGMS) to Neutral from Underweight without a price target The firm says that with the company announcing discontinuation of imvotamab development alongside a pause of its clinical stage IgM assets, it sees its Underweight thesis “now borne out.” Given the uncertain path forward for IGM, JPMorgan no longer ascribes pipeline value in its updated model for shares.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- IGM Biosciences Halts Antibody Therapies, Cuts Workforce
- IGM Biosciences downgraded to Hold from Buy at Jefferies
- AMD downgraded, Nike upgraded: Wall Street’s top analyst calls
- IGM Biosciences price target lowered to $2 from $12 at Truist
- Morning Movers: Constellation Energy climbs following deal to buy Calpine